•   
  •   
  •   

Canada U.S. backs waiver on vaccine patents. What it means and what Canada thinks

23:25  06 may  2021
23:25  06 may  2021 Source:   globalnews.ca

Johnson & Johnson vaccine is coming to Canada. How do we use it best?

  Johnson & Johnson vaccine is coming to Canada. How do we use it best? With an initial shipment of Johnson & Johnson's COVID-19 vaccine due this week — and no word on the next — experts emphasize the need to roll out the shot equitably.Much of the country is in the grips of an alarming third wave. While more vaccines are coming, Johnson & Johnson's (J&J) will offer unique benefits in a time of crisis, said Dr. Isaac Bogoch, an infectious disease specialist based out of Toronto General Hospital.

The world may be inching closer to lifting patent protections for COVID-19 vaccines, and experts in Canada are keen to see the country jump on board.

a woman in a blue shirt: 16 April 2021, North Rhine-Westphalia, Bielefeld: ILLUSTRATION - A nurse draws up the vaccine of the manufacturer Moderna against the coronavirus with a syringe in a posed situation. The 15,000th vaccine can is injected at Bethel in Bielefeld. The district houses workshops for the disabled, hospitals and other social facilities of the von Bodelschwinghschen Stiftungen Bethel and has its own vaccination centre and is thus almost completely vaccinated. Photo: Friso Gentsch/dpa (Photo by Friso Gentsch/picture alliance via Getty Images) © Provided by Global News 16 April 2021, North Rhine-Westphalia, Bielefeld: ILLUSTRATION - A nurse draws up the vaccine of the manufacturer Moderna against the coronavirus with a syringe in a posed situation. The 15,000th vaccine can is injected at Bethel in Bielefeld. The district houses workshops for the disabled, hospitals and other social facilities of the von Bodelschwinghschen Stiftungen Bethel and has its own vaccination centre and is thus almost completely vaccinated. Photo: Friso Gentsch/dpa (Photo by Friso Gentsch/picture alliance via Getty Images)

The U.S. announced Wednesday it now supports a proposal to waive intellectual property (IP) protection to help boost the global COVID-19 vaccine supply. The European Union is also willing to discuss the waiver.

COVID protocol-related absences: 04/27/21

  COVID protocol-related absences: 04/27/21 Each day, the NHL will publicly release the list of players that are unavailable to their respective teams due to being in COVID-19 Protocol. Here is today’s list: Anaheim – Adam Henrique Calgary – Josh Leivo Montreal – TBA New Jersey – P.K.Anaheim – Adam Henrique

Read more: U.S. IP waiver support rocks COVID-19 vaccine makers

The sudden support could kick off a complex -- and potentially bristly -- set of negotiations over sharing patents for the life-saving shots. Patents currently prevent the vaccines from being copied, allowing the originator to be financially rewarded.

"The idea that places like the U.S. and EU -- strong patent holders -- will recognize that there are times when the intellectual property rights need to be superseded by larger global public interest issues... I think it signals something," said Myra Tawfik, a professor at the University of Windsor and an expert in intellectual property law.

"I do think it's a moment of reckoning for Canada."

Canada is holding back its 1-shot J&J COVID-19 vaccine. Here’s what you need to know

  Canada is holding back its 1-shot J&J COVID-19 vaccine. Here’s what you need to know Health Canada on Friday said that they were holding back 300,000 doses of the one-shot J&J vaccine — mere days before they were meant to be deployed.On Friday, Health Canada announced it is holding back the J&J vaccine, a one-shot dose that experts and health officials touted as crucial in stemming the spread of the virus amid a devastating third wave of the pandemic, after it was revealed that parts of the batch were made in the same Baltimore plant where millions of other doses meant for the U.S. market had spoiled.

Richer nations like the U.S. have faced pressure to put weight behind this waiver for months now.

The pleas have come from 100 other countries, led by India and South Africa. They've asked fellow World Trade Organization (WTO) members to agree to a time-limited lifting of COVID-19-related IP rights.

Read more: Canada should ‘join forces’ with U.S. to support waiving COVID-19 vaccine patents, expert says

American support is a "signal that IP rights can legitimately be limited in these kinds of situations," like a public health catastrophe, said Tawfik.

The goal is ultimately to allow nations to produce more vaccines using the formulas and manufacturing techniques that have already been established by pharmaceutical companies. The countries argue that the world's leading vaccine supplies should share their knowledge so that more countries can start producing domestically and for the lowest-income nations.

US backs waiving intellectual property rules on vaccines

  US backs waiving intellectual property rules on vaccines WASHINGTON — The Biden administration on Wednesday joined calls for more sharing of the technology behind COVID-19 vaccines to help speed the end of the pandemic, a shift that puts the U.S. alongside many in the developing world who want rich countries to do more to get doses to the needy. United States Trade Representative Katherine Tai announced the government's position, amid World Trade Organization talks about a possible temporary waiver of its protections that would allow more manufacturers to produce the life-saving vaccines.

The World Health Organization welcomed U.S. President Joe Biden's backing of a waiver. Its head, Tedros Adhanom Ghebreyesus, called it a "monumental moment in the fight against COVID-19."

However, there are hurdles to cross before something like this comes to fruition.

Experts caution that negotiations could take weeks or months.

"Getting something -- anything -- through the WTO takes ages," said Tawfik. "So there will be that issue of how long it will take to actually implement."

Even if they're successful, it remains unknown if developing countries could quickly start manufacturing the complex vaccines.

It's one of the key criticisms coming from the pharmaceutical industry -- that freeing up patents won't magically produce vaccines.

“I am the first one to admit that what we are leaning into is a process that is not going to be easy,” U.S. trade representative Katherine Tai said in an interview Wednesday with Bloomberg.

Read more: World mulls next step after U.S. supports waiving COVID-19 vaccine patents

Canada working on solution for vaccine patent waivers, not ‘blocking’: Trudeau

  Canada working on solution for vaccine patent waivers, not ‘blocking’: Trudeau Trudeau emphasized that Canada is not 'blocking or interfering' in the process over COVID-19 vaccine patent waivers with the WTOThe discussions involve "various different partners who have various different opinions," Trudeau said, and that his government is "working with others around the world to come up with a solution.

Tawfik agrees it's not an immediate solution.

"It's not an easily implementable approach but it speaks volumes," she said. "It puts pressure on the patent holders to work within this understanding that they might need to do better."

The other bridge to cross is unanimity. Technically, any single country could block a decision at the WTO to agree to a waiver.

Canada still hasn't offered direct support of the waiver of IP protections on COVID-19 vaccines, but there is a precedent here.

In 2003, WTO members agreed to waive patent rights and allow poorer countries to import generic treatments for HIV/AIDS, malaria and tuberculosis.

"Canada reacted first, we wanted to do the right thing and got stymied at every turn," said Tawfik.

"Here's an opportunity to challenge the orthodoxy around the patent system, especially the patent system through the trade agreement."

Video: Coronavirus: WHO still needs more funding for vaccine distribution to low-income countries

It depends on the stance Canada chooses to take, Tawfik said. Canada has previously been accused of being too slow to act on this issue.

Trade Minister Mary Ng tweeted following the U.S. announcement, saying Canada actively supports the WTO efforts to accelerate global vaccine production and distribution.

The West Block — Episode 33, Season 10

  The West Block — Episode 33, Season 10 Watch the full episode of The West Block on Sunday, May 9, 2021Episode 33, Season 10

Mark Lievonen, co-chair of Canada's federal COVID-19 vaccine task force, said Tuesday that the transfer of technology would be "time-consuming."

"It certainly wouldn't have gotten us vaccines this year. I don't think it would've gotten us vaccines next year. It is something that's being looked at, as what I would call a medium-term or long-term solution," he said during a committee hearing.

"There were not facilities sitting idling by in Canada that could make the mRNA vaccines."

Read more: Biolyse suggests Health Canada lacks urgency over its ask to produce COVID-19 vaccines for export

Biolyse Pharma, an Ontario-based manufacturer, has been waiting many months to help.

While it's not equipped to make mRNA vaccines, it believes it has the potential to produce up to 20 million doses of a viral-vector vaccine per year -- but it needs access to a patent of an already-approved vaccine to do so.

Biolyse asked Johnson & Johnson in March, but the company declined.

The company says the U.S. support for IP waiving is encouraging.

"Canada needs to get on the plate," Claude Mercure, director of production at Biolyse, told Global News.

"We have difficulty here acquiring vaccines and so on, if anything, they should empathize with other countries facing the same issue."

Video: Biden says he spoke to Trudeau about helping procure COVID-19 vaccines, including offering Canada extra supply

The company is seeking a special, rarely sought licence that would allow it to essentially override a patent and manufacture a generic version of vaccines on its own in order to export them to countries in need. Even if it succeeds in amending the Patent Act list of Schedule I drugs — which has previously taken as long as 15 months — it could face another lengthy hurdle with clinical trials.

Future of AstraZeneca COVID-19 vaccine in question in Canada over blood clots, supply issues

  Future of AstraZeneca COVID-19 vaccine in question in Canada over blood clots, supply issues The future use of the AstraZeneca-Oxford COVID-19 vaccine in Canada is now in question due to concerns over the increased risk of rare but severe blood clots connected to the shot, an unpredictable future supply and a significant amount of alternative vaccines.Alberta was the first province to confirm it would stop administering first doses of the AstraZeneca vaccine, citing a scarcity of supply. The province will instead prioritize mRNA vaccines like Pfizer-BioNTech and Moderna while reserving existing AstraZeneca for second doses.

Mercure said the company has an "open channel of communication" with the federal government, but feels it has "been ghosted more than anything."

"We're a little bit tired, we feel like we wasted time," he said. "Six months ago we could've been producing vaccines for countries in need and we've lost a little bit of the energy."

Tawfik said Canada's support for waiving IP rights would "certainly help" a company like Biolyse.

She said it could allow countries like Canada to "fill the gap" and make generic drugs to help poorer countries, addressing pharmaceutical companies' concerns about some lower-income nations being unequipped to ramp up production quickly.

Read more: Johnson & Johnson’s vaccine won’t be the ‘workhorse’ in Canada’s rollout

So far, drugmakers have argued that the plan is ineffective and that too few countries have the capacity to make more vaccines -- even if they knew the formulas.

Moderna, whose two-dose shot is circulating in many countries worldwide, said Thursday that waiving IP rights on COVID-19 vaccines won't help boost supply this year or next.

The International Federation of Pharmaceutical Manufacturers and Associations told The Associated Press that a waiver would invite new manufacturers that lacked essential know-how and oversight.

Video: Ottawa rolls out plan to produce millions of COVID-19 shots domestically

Countries like Britain and Switzerland, home to large pharmaceutical companies, have opposed the waiver. They argue it would undermine incentives for manufacturers -- which have produced coronavirus vaccines in record time –- to do so in a future pandemic.

Pharmaceutical companies also point to a limited global supply of the materials needed to produce these shots.

Tawfik, whose studies focus on the historical evolution of patent laws, said the system is designed to "encourage socially beneficial outcomes."

"If patent holders are not going to adjust to provide meaningful options to help resolve the pandemic, then governments will step in."

-- with files from The Associated Press, Reuters and Global News' Jacquelyn LeBel and Jackson Proskow

COVID protocol-related absences: 05/13/21 .
Each day, the NHL will publicly release the list of players that are unavailable to their respective teams due to being in COVID-19 Protocol. Here is today’s list: © Isaiah J. Downing-USA TODAY Sports Colorado – Devan DubnykSt. Louis – Jake WalmanWashington – Evgeny KuznetsovAs a reminder, inclusion on this list does not mean that a player has tested positive for Coronavirus or even that they have been confirmed as a close contact to another positive person.

usr: 8
This is interesting!